Estrella Immunopharma (NASDAQ:ESLA) Issues Quarterly Earnings Results

Estrella Immunopharma (NASDAQ:ESLA) issued its earnings results on Thursday. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04, FiscalAI reports.

Estrella Immunopharma Price Performance

NASDAQ:ESLA traded down $0.00 during midday trading on Friday, reaching $0.72. 9,010 shares of the company traded hands, compared to its average volume of 39,046. Estrella Immunopharma has a twelve month low of $0.68 and a twelve month high of $3.15. The firm has a market capitalization of $31.12 million, a price-to-earnings ratio of -3.01 and a beta of 0.88. The company has a fifty day moving average price of $0.88 and a 200 day moving average price of $1.13.

Institutional Investors Weigh In On Estrella Immunopharma

Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its holdings in shares of Estrella Immunopharma by 8.2% during the fourth quarter. Geode Capital Management LLC now owns 109,808 shares of the company’s stock valued at $171,000 after acquiring an additional 8,318 shares during the period. State Street Corp increased its holdings in shares of Estrella Immunopharma by 93.5% in the 4th quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after acquiring an additional 20,900 shares during the period. Quadrature Capital Ltd acquired a new stake in shares of Estrella Immunopharma in the 4th quarter worth about $43,000. XTX Topco Ltd lifted its position in Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock valued at $77,000 after purchasing an additional 39,099 shares during the last quarter. Finally, BlackRock Inc. bought a new stake in Estrella Immunopharma in the 2nd quarter valued at about $54,000. 0.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Estrella Immunopharma has an average rating of “Hold” and an average target price of $8.00.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.